## Joan K Morris

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5824473/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Body-mass index and cause-specific mortality in 900â€^000 adults: collaborative analyses of 57 prospective studies. Lancet, The, 2009, 373, 1083-1096.	13.7	3,779
2	Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ: British Medical Journal, 2009, 338, b1665-b1665.	2.3	2,170
3	Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55â€^000 vascular deaths. Lancet, The, 2007, 370, 1829-1839.	13.7	1,907
4	Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ: British Medical Journal, 2002, 325, 1202-1206.	2.3	1,595
5	Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ: British Medical Journal, 2003, 326, 1427-0.	2.3	962
6	Randomized Trial of Preventive Angioplasty in Myocardial Infarction. New England Journal of Medicine, 2013, 369, 1115-1123.	27.0	871
7	Combination Therapy Versus Monotherapy in Reducing Blood Pressure: Meta-analysis on 11,000 Participants from 42 Trials. American Journal of Medicine, 2009, 122, 290-300.	1.5	747
8	Factors that affect outcome of in-vitro fertilisation treatment. Lancet, The, 1996, 348, 1402-1406.	13.7	639
9	Environmental tobacco smoke exposure and ischaemic heart disease: an evaluation of the evidence. BMJ: British Medical Journal, 1997, 315, 973-980.	2.3	474
10	Valproic Acid Monotherapy in Pregnancy and Major Congenital Malformations. New England Journal of Medicine, 2010, 362, 2185-2193.	27.0	473
11	Low cigarette consumption and risk of coronary heart disease and stroke: meta-analysis of 141 cohort studies in 55 study reports. BMJ: British Medical Journal, 2018, 360, j5855.	2.3	393
12	Reducing the Risk of Multiple Births by Transfer of Two Embryos after in Vitro Fertilization. New England Journal of Medicine, 1998, 339, 573-577.	27.0	392
13	Quantifying the effect of folic acid. Lancet, The, 2001, 358, 2069-2073.	13.7	373
14	Cardiovascular morbidity and mortality after orthotopic liver transplantation. Transplantation, 2002, 73, 901-906.	1.0	297
15	Loss of employment and mortality. BMJ: British Medical Journal, 1994, 308, 1135-1139.	2.3	289
16	Twenty-year trends in the prevalence of Down syndrome and other trisomies in Europe: impact of maternal age and prenatal screening. European Journal of Human Genetics, 2013, 21, 27-33.	2.8	282
17	Prognostic Factors for Poor Cognitive Development in Children Born Very Preterm or With Very Low Birth Weight. JAMA Pediatrics, 2015, 169, 1162.	6.2	271
18	By how much does fruit and vegetable consumption reduce the risk of ischaemic heart disease?. European Journal of Clinical Nutrition, 1998, 52, 549-556.	2.9	255

#	Article	IF	CITATIONS
19	Child–Parent Familial Hypercholesterolemia Screening in Primary Care. New England Journal of Medicine, 2016, 375, 1628-1637.	27.0	250
20	Revised estimates of the maternal age specific live birth prevalence of Down's syndrome. Journal of Medical Screening, 2002, 9, 2-6.	2.3	224
21	ls the prevalence of Klinefelter syndrome increasing?. European Journal of Human Genetics, 2008, 16, 163-170.	2.8	189
22	Fetal loss in Down syndrome pregnancies. Prenatal Diagnosis, 1999, 19, 142-145.	2.3	184
23	Intrauterine exposure to carbamazepine and specific congenital malformations: systematic review and case-control study. BMJ: British Medical Journal, 2010, 341, c6581-c6581.	2.3	179
24	Folic acid, homocysteine, and cardiovascular disease: judging causality in the face of inconclusive trial evidence. BMJ: British Medical Journal, 2006, 333, 1114-1117.	2.3	178
25	Vitamin D supplementation and the prevention of fractures and falls: results of a randomised trial in elderly people in residential accommodation. Age and Ageing, 2006, 35, 482-486.	1.6	169
26	Trends in Down's syndrome live births and antenatal diagnoses in England and Wales from 1989 to 2008: analysis of data from the National Down Syndrome Cytogenetic Register. BMJ: British Medical Journal, 2009, 339, b3794-b3794.	2.3	168
27	Does lamotrigine use in pregnancy increase orofacial cleft risk relative to other malformations?. Neurology, 2008, 71, 714-722.	1.1	151
28	Increasing incidence of tuberculosis in England and Wales: a study of the likely causes. BMJ: British Medical Journal, 1995, 310, 967-969.	2.3	144
29	Cognitive trajectories from infancy to early adulthood following birth before 26 weeks of gestation: a prospective, population-based cohort study. Archives of Disease in Childhood, 2018, 103, 363-370.	1.9	140
30	Randomized Polypill Crossover Trial in People Aged 50 and Over. PLoS ONE, 2012, 7, e41297.	2.5	128
31	Helicobacter pylori infection and mortality from ischaemic heart disease: negative result from a large, prospective study. BMJ: British Medical Journal, 1997, 315, 1199-1201.	2.3	127
32	Non-employment and changes in smoking, drinking, and body weight BMJ: British Medical Journal, 1992, 304, 536-541.	2.3	121
33	A Meta-analysis of Individual Participant Data Reveals an Association between Circulating Levels of IGF-I and Prostate Cancer Risk. Cancer Research, 2016, 76, 2288-2300.	0.9	117
34	The maternal ageâ€specific live birth prevalence of trisomies 13 and 18 compared to trisomy 21 (Down) Tj ETQq	0 0 0 g 2.3 rgB1	Qverlock 10
35	Trends in congenital anomalies in Europe from 1980 to 2012. PLoS ONE, 2018, 13, e0194986.	2.5	106

36 N	The risk of fetal loss following a prenatal diagnosis of trisomy 13 or trisomy 18. American Journal of Medical Genetics, Part A, 2008, 146A, 827-832.	1.2	103
------	--	-----	-----

#	Article	IF	CITATIONS
37	Prognostic factors for cerebral palsy and motor impairment in children born very preterm or very low birthweight: a systematic review. Developmental Medicine and Child Neurology, 2016, 58, 554-569.	2.1	99
38	Screening for Future Cardiovascular Disease Using Age Alone Compared with Multiple Risk Factors and Age. PLoS ONE, 2011, 6, e18742.	2.5	95
39	Changes in atopy over a quarter of a century, based on cross sectional data at three time periods. BMJ: British Medical Journal, 2005, 330, 1187-1188.	2.3	90
40	Serum markers for Down's syndrome in women who have had in vitro fertilisation: implications for antenatal screening. BJOG: an International Journal of Obstetrics and Gynaecology, 1999, 106, 1304-1306.	2.3	89
41	The population prevalence of Down's syndrome in England and Wales in 2011. European Journal of Human Genetics, 2013, 21, 1016-1019.	2.8	88
42	The dose-response relationship between cigarette consumption, biochemical markers and risk of lung cancer. British Journal of Cancer, 1997, 75, 1690-1693.	6.4	85
43	A Prospective Evaluation of Undiagnosed Joint Hypermobility Syndrome in Patients With Gastrointestinal Symptoms. Clinical Gastroenterology and Hepatology, 2014, 12, 1680-1687.e2.	4.4	85
44	Paternal age and birth defects: how strong is the association. Human Reproduction, 2007, 22, 2349-2350.	0.9	84
45	Prevention of Neural Tube Defects: A Cross-Sectional Study of the Uptake of Folic Acid Supplementation in Nearly Half a Million Women. PLoS ONE, 2014, 9, e89354.	2.5	82
46	Why is mortality higher in poorer areas and in more northern areas of England and Wales?. Journal of Epidemiology and Community Health, 1998, 52, 344-352.	3.7	79
47	Maternal ageâ€specific fetal loss rates in Down syndrome pregnancies. Prenatal Diagnosis, 2006, 26, 499-504.	2.3	79
48	Functional gastrointestinal disorders are associated with the joint hypermobility syndrome in secondary care: a case–control study. Neurogastroenterology and Motility, 2015, 27, 569-579.	3.0	79
49	Trajectories of behavior, attention, social and emotional problems from childhood to early adulthood following extremely preterm birth: a prospective cohort study. European Child and Adolescent Psychiatry, 2019, 28, 531-542.	4.7	79
50	Maternal ageâ€specific risk of nonâ€chromosomal anomalies. BJOC: an International Journal of Obstetrics and Gynaecology, 2009, 116, 1111-1119.	2.3	74
51	Comparison of models of maternal age-specific risk for Down syndrome live births. Prenatal Diagnosis, 2003, 23, 252-258.	2.3	73
52	Chlamydia pneumoniae infection and mortality from ischaemic heart disease: large prospective study. BMJ: British Medical Journal, 2000, 321, 204-207.	2.3	68
53	Headaches and the Treatment of Blood Pressure. Circulation, 2005, 112, 2301-2306.	1.6	68
54	Congenital anomalies associated with trisomy 18 or trisomy 13: A registryâ€based study in 16 european countries, 2000–2011. American Journal of Medical Genetics, Part A, 2015, 167, 3062-3069.	1.2	68

#	Article	IF	CITATIONS
55	Public health failure in the prevention of neural tube defects: time to abandon the tolerable upper intake level of folate. Public Health Reviews, 2018, 39, 2.	3.2	68
56	Patient safety and estimation of renal function in patients prescribed new oral anticoagulants for stroke prevention in atrial fibrillation: a cross-sectional study. BMJ Open, 2013, 3, e003343.	1.9	67
57	Use of asthma medication during pregnancy and risk of specific congenital anomalies: AÂEuropean case-malformed control study. Journal of Allergy and Clinical Immunology, 2015, 136, 1496-1502.e7.	2.9	67
58	Reconciling the Evidence on Serum Homocysteine and Ischaemic Heart Disease: A Meta-Analysis. PLoS ONE, 2011, 6, e16473.	2.5	67
59	Mortality in relation to tar yield of cigarettes: a prospective study of four cohorts. BMJ: British Medical Journal, 1995, 311, 1530-1533.	2.3	65
60	Insulin-like growth factors and cancer: no role in screening. Evidence from the BUPA study and meta-analysis of prospective epidemiological studies. British Journal of Cancer, 2006, 95, 112-117.	6.4	64
61	Epidemiology of multiple congenital anomalies in Europe: A EUROCAT populationâ€based registry study. Birth Defects Research Part A: Clinical and Molecular Teratology, 2014, 100, 270-276.	1.6	64
62	The evaluation of cascade testing for familial hypercholesterolemia. American Journal of Medical Genetics, Part A, 2012, 158A, 78-84.	1.2	63
63	Long-term survival of children born with congenital anomalies: A systematic review and meta-analysis of population-based studies. PLoS Medicine, 2020, 17, e1003356.	8.4	63
64	Problems in conducting economic evaluations alongside clinical trials. British Journal of Psychiatry, 1997, 170, 47-52.	2.8	62
65	Prevalence and risk of <scp>D</scp> own syndrome in monozygotic and dizygotic multiple pregnancies in <scp>E</scp> urope: implications for prenatal screening. BJOG: an International Journal of Obstetrics and Gynaecology, 2014, 121, 809-820.	2.3	60
66	Lamotrigine use in pregnancy and risk of orofacial cleft and other congenital anomalies. Neurology, 2016, 86, 1716-1725.	1.1	59
67	Trisomy 13 and 18—Prevalence and mortality—A multiâ€registry population based analysis. American Journal of Medical Genetics, Part A, 2019, 179, 2382-2392.	1.2	59
68	Major congenital anomalies in babies born with Down syndrome: A EUROCAT populationâ€based registry study. American Journal of Medical Genetics, Part A, 2014, 164, 2979-2986.	1.2	57
69	Prevalence of microcephaly in Europe: population based study. BMJ, The, 2016, 354, i4721.	6.0	57
70	Grapefruit Juice and Statins. American Journal of Medicine, 2016, 129, 26-29.	1.5	57
71	Risk Factor Models for Neurodevelopmental Outcomes in Children Born Very Preterm or With Very Low Birth Weight: A Systematic Review of Methodology and Reporting. American Journal of Epidemiology, 2017, 185, 601-612.	3.4	55
72	Prognostic Factors for Behavioral Problems and Psychiatric Disorders in Children Born Very Preterm or Very Low Birth Weight. Journal of Developmental and Behavioral Pediatrics, 2016, 37, 88-102.	1.1	53

#	Article	IF	CITATIONS
73	Haemoglobin level at birth is associated with short term outcomes and mortality in preterm infants. BMC Medicine, 2015, 13, 16.	5.5	52
74	Survival of trisomy 18 (Edwards syndrome) and trisomy 13 (Patau Syndrome) in England and Wales: 2004–2011. American Journal of Medical Genetics, Part A, 2013, 161, 2512-2518.	1.2	51
75	Trends in maternal age distribution and the live birth prevalence of Down's syndrome in England and Wales: 1938–2010. European Journal of Human Genetics, 2013, 21, 943-947.	2.8	50
76	The efficacy of combining several risk factors as a screening test. Journal of Medical Screening, 2005, 12, 197-201.	2.3	49
77	Recurrence risks for trisomies 13, 18, and 21. American Journal of Medical Genetics, Part A, 2009, 149A, 2716-2722.	1.2	49
78	Estimating the birth prevalence and pregnancy outcomes of congenital malformations worldwide. Journal of Community Genetics, 2018, 9, 387-396.	1.2	48
79	Prevention of neural tube defects in the UK: a missed opportunity. Archives of Disease in Childhood, 2016, 101, 604-607.	1.9	46
80	A sustainable solution for the activities of the European network for surveillance of congenital anomalies: EUROCAT as part of the EU Platform on Rare Diseases Registration. European Journal of Medical Genetics, 2018, 61, 513-517.	1.3	45
81	Fetal loss in Down syndrome pregnancies. Prenatal Diagnosis, 1999, 19, 142-5.	2.3	45
82	Serum Albumin and Mortality in the BUPA Study. International Journal of Epidemiology, 1994, 23, 38-41.	1.9	44
83	Teleoanalysis: combining data from different types of study. BMJ: British Medical Journal, 2003, 327, 616-618.	2.3	43
84	Quantifying the decline in the birth prevalence of neural tube defects in England and Wales. Journal of Medical Screening, 1999, 6, 182-185.	2.3	42
85	Selective Serotonin Reuptake Inhibitor (SSRI) Antidepressants in Pregnancy and Congenital Anomalies: Analysis of Linked Databases in Wales, Norway and Funen, Denmark. PLoS ONE, 2016, 11, e0165122.	2.5	42
86	Assessing Risk Factors as Potential Screening Tests. Archives of Internal Medicine, 2011, 171, 286.	3.8	40
87	The dose-response relation between serum homocysteine and cardiovascular disease: implications for treatment and screening. European Journal of Cardiovascular Prevention and Rehabilitation, 2004, 11, 250-253.	2.8	38
88	Screening in early pregnancy for preâ€eclampsia using down syndrome quadruple test markers. Prenatal Diagnosis, 2006, 26, 559-564.	2.3	38
89	De novo apparently balanced translocations in man are predominantly paternal in origin and associated with a significant increase in paternal age. Journal of Medical Genetics, 2010, 47, 112-115.	3.2	38
90	Multiple marker second trimester serum screening for pre-eclampsia. Journal of Medical Screening, 2001, 8, 65-68.	2.3	37

6

#	Article	IF	CITATIONS
91	Prevalence of neural tube defect pregnancies in England and Wales from 1964 to 2004. Journal of Medical Screening, 2007, 14, 55-59.	2.3	33
92	Cytogenetic and epidemiological findings in Down syndrome: England and Wales 1989–2009. American Journal of Medical Genetics, Part A, 2012, 158A, 1151-1157.	1.2	33
93	Birth prevalence and survival of exomphalos in england and wales: 2005 to 2011. Birth Defects Research Part A: Clinical and Molecular Teratology, 2014, 100, 721-725.	1.6	33
94	Chromosomal disorders: estimating baseline birth prevalence and pregnancy outcomes worldwide. Journal of Community Genetics, 2018, 9, 377-386.	1.2	33
95	Risk of congenital anomalies after exposure to asthma medication in the first trimester of pregnancy – a cohort linkage study. BJOG: an International Journal of Obstetrics and Gynaecology, 2016, 123, 1609-1618.	2.3	32
96	EUROlinkCAT protocol for a European population-based data linkage study investigating the survival, morbidity and education of children with congenital anomalies. BMJ Open, 2021, 11, e047859.	1.9	31
97	A three-year prospective study of the presentation and clinical outcomes of major bleeding episodes associated with oral anticoagulant use in the UK (ORANGE study). Haematologica, 2018, 103, 738-745.	3.5	30
98	Prenatal screening for serious congenital heart defects using nuchal translucency: a metaâ€analysis. Prenatal Diagnosis, 2008, 28, 1094-1104.	2.3	29
99	An Emmonsia Species Causing Disseminated Infection in South Africa. New England Journal of Medicine, 2014, 370, 283-284.	27.0	29
100	Detection and investigation of temporal clusters of congenital anomaly in Europe: seven years of experience of the EUROCAT surveillance system. European Journal of Epidemiology, 2015, 30, 1153-1164.	5.7	29
101	A systematic review and meta-analyses of pregnancy and fetal outcomes in women with multiple sclerosis: a contribution from the IMI2 ConcePTION project. Journal of Neurology, 2020, 267, 2721-2731.	3.6	29
102	EUROCAT: an update on its functions and activities. Journal of Community Genetics, 2018, 9, 407-410.	1.2	28
103	Beckwith Wiedemann syndrome: A population-based study on prevalence, prenatal diagnosis, associated anomalies and survival in Europe. European Journal of Medical Genetics, 2018, 61, 499-507.	1.3	28
104	Risk of a Down syndrome live birth in women 45 years of age and older. Prenatal Diagnosis, 2005, 25, 275-278.	2.3	27
105	Case-control analysis of paternal age and trisomic anomalies. Archives of Disease in Childhood, 2010, 95, 893-897.	1.9	27
106	Recurrences of free trisomy 21: analysis of data from the National Down Syndrome Cytogenetic Register. Prenatal Diagnosis, 2005, 25, 1120-1128.	2.3	26
107	Epidemiology of septo-optic dysplasia with focus on prevalence and maternal age – A EUROCAT study. European Journal of Medical Genetics, 2018, 61, 483-488	1.3	26
108	Cost Comparison of Different Methods of Screening for Cystic Fibrosis. Journal of Medical Screening, 1995, 2, 22-27.	2.3	25

#	Article	IF	CITATIONS
109	The importance of age in screening for cancer. Journal of Medical Screening, 1999, 6, 16-20.	2.3	24
110	Cystic fibrosis: selecting the prenatal screening strategy of choice. Prenatal Diagnosis, 2003, 23, 474-483.	2.3	24
111	Graphical presentation of distributions of risk in screening. Journal of Medical Screening, 2005, 12, 155-160.	2.3	24
112	Prenatal reflex DNA screening for trisomies 21, 18, and 13. Genetics in Medicine, 2018, 20, 825-830.	2.4	24
113	Epidemiology of congenital cerebral anomalies in Europe: a multicentre, population-based EUROCAT study. Archives of Disease in Childhood, 2019, 104, 1181-1187.	1.9	24
114	Is cascade testing a sensible method of screening a population for autosomal recessive disorders?. American Journal of Medical Genetics Part A, 2004, 128A, 271-275.	2.4	23
115	Corrections to maternal age-specific live birth prevalence of Down's syndrome. Journal of Medical Screening, 2005, 12, 202-202.	2.3	23
116	Ascertainment and accuracy of Down syndrome cases reported in congenital anomaly registers in England and Wales. Archives of Disease in Childhood: Fetal and Neonatal Edition, 2008, 94, F23-F27.	2.8	23
117	De novo deletions and duplications detected by array CGH: a study of parental origin in relation to mechanisms of formation and size of imbalance. European Journal of Human Genetics, 2012, 20, 155-160.	2.8	23
118	Prevention of Neural Tube Defects in Europe: A Public Health Failure. Frontiers in Pediatrics, 2021, 9, 647038.	1.9	23
119	Cost–benefit analysis of the polypill in the primary prevention of myocardial infarction and stroke. European Journal of Epidemiology, 2016, 31, 415-426.	5.7	22
120	The performance of blood pressure and other cardiovascular risk factors as screening tests for ischaemic heart disease and stroke. Journal of Medical Screening, 2004, 11, 3-7.	2.3	21
121	The association between Ehlersâ€Danlos syndrome—hypermobility type and gastrointestinal symptoms in university students: a crossâ€sectional study. Neurogastroenterology and Motility, 2017, 29, e12942.	3.0	21
122	Linking a European cohort of children born with congenital anomalies to vital statistics and mortality records: A EUROlinkCAT study. PLoS ONE, 2021, 16, e0256535.	2.5	21
123	Sources of T1 variance in normal human white matter. Magnetic Resonance Imaging, 1991, 9, 53-59.	1.8	20
124	Cross-trimester marker ratios in prenatal screening for Down syndrome. Prenatal Diagnosis, 2006, 26, 514-523.	2.3	20
125	Cytological and epidemiological findings in trisomies 13, 18, and 21: England and Wales 2004–2009. American Journal of Medical Genetics, Part A, 2012, 158A, 1145-1150.	1.2	19
126	Quantifying the health benefits of chronic disease prevention: a fresh approach using cardiovascular disease as an example. European Journal of Epidemiology, 2014, 29, 605-612.	5.7	19

#	Article	IF	CITATIONS
127	Down syndrome birth weight in England and Wales: Implications for clinical practice. American Journal of Medical Genetics, Part A, 2015, 167, 3070-3075.	1.2	19
128	Insulin analogues use in pregnancy among women with pregestational diabetes mellitus and risk of congenital anomaly: a retrospective population-based cohort study. BMJ Open, 2018, 8, e014972.	1.9	19
129	An overview of concepts and approaches used in estimating the burden of congenital disorders globally. Journal of Community Genetics, 2018, 9, 347-362.	1.2	19
130	Growth to early adulthood following extremely preterm birth: the EPICure study. Archives of Disease in Childhood: Fetal and Neonatal Edition, 2020, 105, 496-503.	2.8	19
131	Revised estimates of the risk of fetal loss following a prenatal diagnosis of trisomy 13 or trisomy 18. American Journal of Medical Genetics, Part A, 2017, 173, 953-958.	1.2	18
132	Prescription of antiepileptic medicines including valproate in pregnant women: A study in three European countries. Pharmacoepidemiology and Drug Safety, 2019, 28, 1510-1518.	1.9	18
133	Size at birth, growth trajectory in early life, and cardiovascular and metabolic risks in early adulthood: EPICure study. Archives of Disease in Childhood: Fetal and Neonatal Edition, 2021, 106, 149-155.	2.8	18
134	Ten-Year Survival of Children With Congenital Anomalies: A European Cohort Study. Pediatrics, 2022, 149, .	2.1	18
135	Is there evidence of clustering in Down syndrome?. International Journal of Epidemiology, 1998, 27, 495-498.	1.9	17
136	Collaborative overview (â€~Meta-Analysis') of Prospective Observational Studies of the Associations of Usual Blood Pressure and Usual Cholesterol Levels with Common Causes of Death: Protocol for the Second Cycle of the Prospective Studies Collaboration. European Journal of Cardiovascular Prevention and Rehabilitation, 1999, 6, 315-320.	2.8	17
137	Down syndrome and paternal age, a new analysis of case–control data collected in the 1960s. American Journal of Medical Genetics, Part A, 2009, 149A, 1205-1208.	1.2	17
138	Prevention of Late Onset Sepsis and Central-line Associated Blood Stream Infection in Preterm Infants. Pediatric Infectious Disease Journal, 2016, 35, 401-406.	2.0	17
139	EUROmediCAT signal detection: an evaluation of selected congenital anomalyâ€medication associations. British Journal of Clinical Pharmacology, 2016, 82, 1094-1109.	2.4	17
140	Community water fluoridation and health outcomes in England: a crossâ€sectional study. Community Dentistry and Oral Epidemiology, 2015, 43, 550-559.	1.9	16
141	In vivo T1 values from guinea pig brain depend on body temperature. Magnetic Resonance in Medicine, 1992, 24, 170-173.	3.0	15
142	The population impact of screening for Down syndrome: audit of 19 326 invasive diagnostic tests in England and Wales in 2008. Prenatal Diagnosis, 2012, 32, 596-601.	2.3	15
143	Did advice on the prescription of sodium valproate reduce prescriptions to women? An observational study in three European countries between 2007 and 2016. Pharmacoepidemiology and Drug Safety, 2019, 28, 1519-1528.	1.9	15
144	Haematological management of major bleeding associated with direct oral anticoagulants – UK experience. British Journal of Haematology, 2019, 185, 514-522.	2.5	15

#	Article	IF	CITATIONS
145	European trends in mortality in children with congenital anomalies: 2000–2015. Birth Defects Research, 2021, 113, 958-967.	1.5	15
146	Estimation of sodium excretion should be made as simple as possible, but not simpler. Journal of Hypertension, 2015, 33, 884-886.	0.5	14
147	Monitoring Trends in Prenatal Diagnosis of Down's Syndrome in England and Wales, 1989–92. Journal of Medical Screening, 1994, 1, 233-237.	2.3	13
148	A new approach to antenatal screening for Fragile X syndrome. Prenatal Diagnosis, 2003, 23, 345-351.	2.3	13
149	The value of early second trimester PAPP-A and ADAM12 in screening for pre-eclampsia. Journal of Medical Screening, 2012, 19, 51-54.	2.3	13
150	Preventive Angioplasty in Myocardial Infarction. New England Journal of Medicine, 2014, 370, 280-283.	27.0	13
151	Occupational Exposure to Hydrazine and Subsequent Risk of Lung Cancer: 50-Year Follow-Up. PLoS ONE, 2015, 10, e0138884.	2.5	13
152	ZikaPLAN: addressing the knowledge gaps and working towards a research preparedness network in the Americas. Global Health Action, 2019, 12, 1666566.	1.9	13
153	Maternal age in the epidemiology of common autosomal trisomies. Prenatal Diagnosis, 2021, 41, 573-583.	2.3	13
154	By how much does fruit and vegetable consumption reduce the risk of ischaemic heart disease: Response to commentary. European Journal of Clinical Nutrition, 1999, 53, 903-904.	2.9	12
155	Antenatal detection of Edwards (Trisomy 18) and Patau (Trisomy 13) syndrome: England and Wales 2005-2012. Journal of Medical Screening, 2014, 21, 113-119.	2.3	12
156	Should Testicular Self Examination Be Recommended?. Journal of Medical Screening, 1996, 3, 2-2.	2.3	11
157	Signal Detection in EUROmediCAT: Identification and Evaluation of Medication–Congenital Anomaly Associations and Use of VigiBase as a Complementary Source of Reference. Drug Safety, 2021, 44, 765-785.	3.2	11
158	Reliability of Statistics on Down's Syndrome Notifications. Journal of Medical Screening, 1997, 4, 95-97.	2.3	10
159	Serum homocysteine and the severity of coronary artery disease. Thrombosis Research, 2003, 111, 55-57.	1.7	10
160	Lowering blood pressure to prevent myocardial infarction and stroke: A new preventive strategy. International Journal of Technology Assessment in Health Care, 2005, 21, 145-145.	0.5	10
161	Body weight reduction to avoid the excess risk of type 2 diabetes. British Journal of General Practice, 2012, 62, e411-e414.	1.4	10
162	Management and outcomes of neonates with down syndrome admitted to neonatal units. Birth Defects Research Part A: Clinical and Molecular Teratology, 2016, 106, 468-474.	1.6	10

#	Article	IF	CITATIONS
163	EUROmediCAT signal detection: a systematic method for identifying potential teratogenic medication. British Journal of Clinical Pharmacology, 2016, 82, 1110-1122.	2.4	10
164	Evaluation of stability of directly standardized rates for sparse data using simulation methods. Population Health Metrics, 2018, 16, 19.	2.7	10
165	Temporal and geographical variations in survival of children born with congenital anomalies in Europe: A multiâ€registry cohort study. Paediatric and Perinatal Epidemiology, 2022, 36, 792-803.	1.7	10
166	Is cascade testing a sensible method of population screening?. Journal of Medical Screening, 2004, 11, 57-58.	2.3	9
167	Down's syndrome: screening and antenatal diagnosis regionally in England and Wales 1989–2008. Journal of Medical Screening, 2010, 17, 170-175.	2.3	9
168	Aspirin in the prevention of cancer. Lancet, The, 2011, 377, 1649.	13.7	9
169	Use of infectious disease surveillance reports to monitor the Zika virus epidemic in Latin America and the Caribbean from 2015 to 2017: strengths and deficiencies. BMJ Open, 2020, 10, e042869.	1.9	9
170	Potential biases in Down syndrome birth prevalence estimation. Journal of Medical Screening, 2002, 9, 192-192.	2.3	8
171	Mortality from hypertrophic cardiomyopathy in England and Wales: clinical and screening implications. International Journal of Cardiology, 2004, 97, 479-484.	1.7	8
172	Calcium channel blockers and headache. British Journal of Clinical Pharmacology, 2007, 63, 157-158.	2.4	8
173	Trisomy 21 mosaicism and maternal age. American Journal of Medical Genetics, Part A, 2012, 158A, 2482-2484.	1.2	8
174	Mortality from aortic stenosis: prospective study of serum calcium and phosphate. Journal of Internal Medicine, 2017, 281, 407-411.	6.0	8
175	Urgent need for folic acid fortification of flour and grains: response to the 2019 UK Government's public consultation. Archives of Disease in Childhood, 2020, 105, 6-9.	1.9	8
176	Regional differences in short stature in England between 2006 and 2019: A cross-sectional analysis from the National Child Measurement Programme. PLoS Medicine, 2021, 18, e1003760.	8.4	8
177	Prevalence and severity of dental fluorosis in four English cities. Community Dental Health, 2016, 33, 292-296.	0.2	8
178	Changes in maternal age in England and Wales - implications for Down syndrome. Down Syndrome Research and Practice, 2006, 10, 41-43.	0.3	8
179	Prevalence of Down's Syndrome in England, 1998–2013. International Journal of Population Data Science, 2020, 5, 1157.	0.1	8
180	COVIDâ€19 in pregnancy—what study designs can we use to assess the risk of congenital anomalies in relation to COVIDâ€19 disease, treatment and vaccination?. Paediatric and Perinatal Epidemiology, 2022, 36, 493-507.	1.7	8

#	Article	IF	CITATIONS
181	Survival of children with rare structural congenital anomalies: a multi-registry cohort study. Orphanet Journal of Rare Diseases, 2022, 17, 142.	2.7	8
182	What is Case—Finding?. Journal of Medical Screening, 1996, 3, 1-1.	2.3	7
183	Validation plots in antenatal screening for Down's syndrome. Journal of Medical Screening, 2006, 13, 166-171.	2.3	7
184	Fetal loss in Down syndrome pregnancies. Prenatal Diagnosis, 1999, 19, 142-145.	2.3	7
185	Three stage contingent screening for Down syndrome. Prenatal Diagnosis, 2006, 26, 1183-1183.	2.3	6
186	Estimating the risk of Down's syndrome in antenatal screening and the gestation at which this risk applies. Journal of Medical Screening, 2007, 14, 5-7.	2.3	6
187	Screening for pre-eclampsia using serum placental growth factor and endoglin with Down's syndrome Quadruple test markers. Journal of Medical Screening, 2012, 19, 60-67.	2.3	6
188	Screening for Malignant Melanoma. Journal of Medical Screening, 1994, 1, 2-2.	2.3	5
189	The Association of H1N1 Pandemic Influenza with Congenital Anomaly Prevalence in Europe. Epidemiology, 2015, 26, 853-861.	2.7	5
190	Starting the polypill: the use of a single age cut-off in males and females. Journal of Medical Screening, 2017, 24, 50-53.	2.3	5
191	Early echocardiography does not predict subsequent treatment of symptomatic patent ductus arteriosus in extremely preterm infants. Acta Paediatrica, International Journal of Paediatrics, 2018, 107, 1909-1916.	1.5	5
192	Projected number of children with isolated spina bifida or down syndrome in England and Wales by 2020. European Journal of Medical Genetics, 2018, 61, 539-545.	1.3	5
193	Passive smoking and heart disease. BMJ: British Medical Journal, 1998, 317, 344-344.	2.3	5
194	Non-consulters and high consulters in general practice: cardio-respiratory health and risk factors. Journal of Public Health Medicine, 1992, 14, 131-7.	0.4	5
195	The effect of correlations between screening markers on screening performance. Journal of Medical Screening, 2007, 14, 151-157.	2.3	4
196	A 16-week, randomized, double-blind, placebo-controlled, crossover trial to quantify the combined effect of an angiotensin-converting enzyme inhibitor and a β-blocker on blood pressure reduction. Clinical Therapeutics, 2008, 30, 2030-2039.	2.5	4
197	Commentary: Clustering in Down syndrome. International Journal of Epidemiology, 2008, 37, 1179-1180.	1.9	4
198	Multiple-marker screening for Down's syndrome: a method of assessing the statistical robustness of proposed tests. Journal of Medical Screening, 2008, 15, 55-61.	2.3	4

#	Article	IF	CITATIONS
199	Antenatal screening for Down syndrome: A quantitative demonstration of the improvements over the past 20 years. Journal of Health Services Research and Policy, 2013, 18, 195-201.	1.7	4
200	Accuracy of reporting abortions with Down syndrome in England and Wales: a data linkage study. Journal of Public Health, 2016, 38, 170-174.	1.8	4
201	"Polypill" to fight cardiovascular disease: Authors' reply. BMJ: British Medical Journal, 2003, 327, 809-a-810.	2.3	4
202	Response to Walker. Genetics in Medicine, 2018, 20, 1295-1295.	2.4	4
203	Down syndrome fetal loss rate in early pregnancy. Prenatal Diagnosis, 2000, 20, 685-686.	2.3	3
204	Screening for neuroblastoma in children. Journal of Medical Screening, 2002, 9, 56-56.	2.3	3
205	Interpretation of reported live birth maternal age-specific rates on an ostensibly white population in data from the National ?Down syndrome? Register. Prenatal Diagnosis, 2004, 24, 1017-1018.	2.3	3
206	The proportions of Down's syndrome pregnancies detected prenatally in England and Wales from 1989 to 2004. Journal of Medical Screening, 2006, 13, 163-165.	2.3	3
207	Valproic Acid Monotherapy in Pregnancy and Major Congenital Malformations. Obstetrical and Gynecological Survey, 2010, 65, 619-620.	0.4	3
208	Cost-effectiveness of diagnosis of high blood pressure in primary care. Lancet, The, 2012, 379, 709-710.	13.7	3
209	Personalized medicine: hope or hype. European Heart Journal, 2012, 33, 1553-1554.	2.2	3
210	Use of hierarchical models to analyze European trends in congenital anomaly prevalence. Birth Defects Research Part A: Clinical and Molecular Teratology, 2016, 106, 480-488.	1.6	3
211	Prevalence of valproate syndrome in Europe from 2005 to 2014: A registry based multi-centre study. European Journal of Medical Genetics, 2018, 61, 479-482.	1.3	3
212	Identifying signals of potentially harmful medications in pregnancy: use of the double false discovery rate method to adjust for multiple testing. British Journal of Clinical Pharmacology, 2019, 85, 356-365.	2.4	3
213	Two under-recognized limitations of number needed to treat. International Journal of Epidemiology, 2020, 49, 359-360.	1.9	3
214	Folate and risk of cardiovascular disease. BMJ: British Medical Journal, 2003, 326, 1035a-1035.	2.3	3
215	Reply to Professor Hook. Prenatal Diagnosis, 2004, 24, 1018-1018.	2.3	2
216	Screening approach for Fragile X syndrome. Prenatal Diagnosis, 2004, 24, 67-68.	2.3	2

#	Article	IF	CITATIONS
217	Rates of Down syndrome at the upper extreme of maternal age: considerations and recommendations in analysis. Prenatal Diagnosis, 2006, 26, 1091-1091.	2.3	2
218	Refining the American guidelines for prevention of cardiovascular disease. Lancet, The, 2014, 383, 598.	13.7	2
219	Prevalence of microcephaly: the Latin American Network of Congenital Malformations 2010–2017. BMJ Paediatrics Open, 2021, 5, e001235.	1.4	2
220	Prescription of cardiovascular medication in children with congenital heart defects across six European Regions from 2000 to 2014: data from the EUROlinkCAT population-based cohort study. BMJ Open, 2022, 12, e057400.	1.9	2
221	Review: lower dose combination antihypertensive therapy is preferable to standard dose single drug therapy. Evidence-Based Medicine, 2004, 9, 11-11.	0.6	1
222	Cross trimester marker ratios: parameter estimates valid with no inconsistency. Prenatal Diagnosis, 2006, 26, 994-994.	2.3	1
223	Truncation limits for CT marker ratios in prenatal screening for Down syndrome. Prenatal Diagnosis, 2007, 27, 187-188.	2.3	1
224	Reply to Herlihy and Halliday. European Journal of Human Genetics, 2008, 16, 1174-1174.	2.8	1
225	Increasing body weight: 1989–2008. International Journal of Clinical Practice, 2010, 64, 408-409.	1.7	1
226	Newer anticonvulsants: Lamotrigine. Birth Defects Research Part A: Clinical and Molecular Teratology, 2012, 94, 959-959.	1.6	1
227	Letters to the editor. Journal of the Royal College of Physicians of Edinburgh, The, 2013, 43, 94-95.	0.6	1
228	Oral anticoagulant agentâ€associated bleeding events reporting system ( <scp>ORANGE</scp> ) study. British Journal of Haematology, 2014, 167, 274-276.	2.5	1
229	The impact of providing blood to the scene of an accident on transfusion laboratory practice. Transfusion Medicine, 2018, 28, 56-59.	1.1	1
230	Investigation of EEG Activity Compared with Mean Arterial Blood Pressure in Extremely Preterm Infants. Frontiers in Neurology, 2018, 9, 87.	2.4	1
231	Serum homocysteine and coronary heart disease. , 2005, , 239-250.		1
232	Blood pressure meta-analysis highlights an implementation gap. Lancet, The, 2022, 399, 1379-1380.	13.7	1
233	Castrostomy and congenital anomalies: a European population-based study. BMJ Paediatrics Open, 2022, 6, e001526.	1.4	1
234	Screening for Neuroblastoma in Children. Journal of Medical Screening, 1994, 1, 141-142.	2.3	0

#	Article	IF	CITATIONS
235	Incidence Oftesticular Cancer. Journal of Medical Screening, 1996, 3, 165-165.	2.3	Ο
236	Screening for Neuroblastoma in Children. Journal of Medical Screening, 1997, 4, 115-116.	2.3	0
237	Reply: Prenatal screen for Fragile X syndrome. Prenatal Diagnosis, 2004, 24, 68-69.	2.3	0
238	When screening is still not enough. Journal of Medical Screening, 2006, 13, 55-55.	2.3	0
239	Meta-analysis audit trail. Lancet, The, 2008, 371, 558.	13.7	0
240	Maternal Age-Specific Risk of Nonchromosomal Anomalies. Obstetrical and Gynecological Survey, 2009, 64, 650-651.	0.4	0
241	Blood pressures in subjects for life assurance medical examination and the effect of ten minutes recumbent rest. Journal of the Royal College of Physicians of Edinburgh, The, 2012, 42, 205-210.	0.6	0
242	PTU-124â€The Association of the Joint Hypermobility Syndrome with Functional Gastrointestinal Disorders – an Interesting New finding that may Explain Aetiology. Gut, 2013, 62, A97.1-A97.	12,1	0
243	Analysis of the Born in Bradford birth cohort. Lancet, The, 2014, 383, 122-123.	13.7	0
244	Increasing body weight. International Journal of Clinical Practice, 2015, 69, 148-149.	1.7	0
245	The Reply. American Journal of Medicine, 2016, 129, e303.	1.5	0
246	Reply. Journal of Allergy and Clinical Immunology, 2016, 137, 1624-1625.	2.9	0
247	Is a prenatal diagnosis detrimental to the survival of a fetus with trisomy 18?. American Journal of Medical Genetics, Part A, 2016, 170, 850-851.	1.2	0
248	OC-59â€Born at the threshold of viability: the impact on cognitive development into adulthood. , 2017, , .		0
249	The Need to Interpret the Results of a Clinical Trial in the Context of Other Evidence. American Journal of Medicine, 2017, 130, 251-252.	1.5	0
250	Bayesian hierarchical methods in the detection of potentially teratogenic firstâ€ŧrimester medications. Pharmacoepidemiology and Drug Safety, 2020, 29, 337-346.	1.9	0
251	Letters to the editor. Journal of the Royal College of Physicians of Edinburgh, The, 2013, 43, 283-285.	0.6	0
252	Reasons for increased incidence of tuberculosis. BMJ: British Medical Journal, 1995, 311, 688-688.	2.3	0

#	Article	IF	CITATIONS
253	Couple screening should be preferred for medical reasons. BMJ: British Medical Journal, 1996, 312, 908-909.	2.3	0
254	Multi-marker risk-based screening for prostate cancer. Journal of Medical Screening, 2022, , 096914132210764.	2.3	0